What is known on this topic:
• Platelet activation in response to stimulation of the Protease Activated Receptor 4 (PAR4) receptor differs by race.
• Phosphatidylcholine Transfer Protein (PCTP), a regulator of PAR4 signaling, is differentially expressed by race.
• Genetic variants can affect transcriptional activity by altering regulatory regions of DNA. What this paper adds:
• Identifies the variant rs2912553 as contributing to racially differential expression of PCTP.
• Identifies differential binding of a GATA1-containing complex dependent on rs2912553 genotype. 3 
Summary
Platelet activation in response to stimulation of the Protease Activated Receptor 4 (PAR4)
receptor differs by race. One factor that contributes to this difference is the expression level of Phosphatidylcholine Transfer Protein (PCTP), a regulator of platelet PAR4 function. We have conducted an expression Quantitative Trait Locus (eQTL) analysis that identifies single nucleotide polymorphisms (SNPs) linked to the expression level of platelet genes. This analysis revealed 26 SNPs associated with the expression level of PCTP at genome-wide significance (P < 5x10 -8 ). Using annotation from ENCODE and other public data we prioritized one of these SNPs, rs2912553, for functional testing. The allelic frequency of rs2912553 is racially-dimorphic, in concordance with the racially differential expression of PCTP. Reporter gene assays confirmed
Introduction
Genome wide association studies (GWAS) seek to find associations between regions of the genome and normal or pathological traits. There are several challenges associated with GWAS including the requirement of large sample sizes and/or effect sizes to achieve statistical significance. One approach to overcome this challenge is to first identify associations between gene expression and the phenotype of interest using expression profiling analysis. This is followed by expression quantitative trait loci (eQTL) analysis, which uncovers associations between genetic variants and gene expression. This indirect approach can lead to the identification of genetic variants that affect physiology in a manner that requires smaller sample sizes than traditional GWAS (1) .
Another challenge in GWAS is deciphering the mechanism by which a genetic variant exerts its effect on the phenotype. This is complicated by the fact that 98% of SNPs identified in GWAS are located in non-protein coding portions of the genome. A relationship between genotype, gene expression, and phenotype indicates that the variant acts through a transcriptionbased mechanism. Efforts by the ENCODE project and others have begun to provide annotation to non-coding regions of the genome, identifying DNA-binding proteins, chromatin modifications, and other epigenetic marks located throughout the genome (2, 3). Localization of eQTLs within these annotated regions facilitates prioritization for testing, experimental design, and variant functionalization.
We have previously conducted a gene expression profiling study to identify platelet RNAs that are differentially expressed by demographic variables or associated with platelet physiological phenotypes, called the Platelet RNA And eXpression (PRAX1) study (4, 5) . Using this approach, we were able to identify the expression level of the PCTP gene, encoding
Phosphatidyl Choline Transfer Protein (PC-TP), as being positively associated with platelet reactivity in response to Protease Activated Receptor 4 (PAR4) thrombin receptor stimulation.
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PCTP RNA was also more highly expressed among self-identified black subjects as compared to self-identified whites, in concordance with our finding that PAR4 stimulation induced platelet aggregation more robustly in blacks than whites. The role of PC-TP protein in regulating PAR-4 function has been confirmed both by pharmacological inhibition and by siRNA silencing (4).
By performing an eQTL analysis of the PRAX1 cohort, several single nucleotide polymorphisms (SNPs) were identified as associated with PCTP RNA levels (6) . We now report identification of the mechanism by which a common genetic variant contributes to differential PCTP expression. Using a combination of publically available data, reporter gene assays and electromobility shift assays (EMSA), we have confirmed that SNP rs2912553 confers differential transcriptional potency to the locus surrounding it. rs2912553 genotype results in differential recruitment of a GATA-1 containing complex which regulates transcription at this locus.
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Materials and Methods
The Platelet RNA and eXpression Study 1 (PRAX1) DNA from the buffy coats of PRAX1 subjects was hybridized to the HumanOmni5 array (Illumina Inc., San Diego, CA) as described earlier (4) and genotyped for approximately five million markers. Genotype data was restricted to 1927172 markers passing a cohort-specific minor allele frequency cutoff of 5%. Gene expression of PRAX1 samples was measured using the Human Gene 1.0 ST microarray (Affymetrix, Santa Clara, CA) as described previously (5) Detailed primer information is shown in Table 1 . were resolved on a 12% SDS-PAGE gel. The PVDF membrane was then probed with antibodies directed against PC-TP, GATA1, and internal loading control, GAPDH (Santa Cruz Biotechnology Dallas, TX). The blot was scanned and bands quantified using a LI-COR Odyssey imaging system (Lincoln, NE).
Results
Identification and annotation of eQTLs associated with PCTP expression.
To better understand the genetic mechanisms responsible for variation in PCTP expression we performed an eQTL analysis to identify associations between PCTP RNA levels and SNPs located within 500kb of the PCTP gene (6, 8) . This resulted in the identification of 26
SNPs whose P-value for association with PCTP RNA levels met genome-wide significance (P < 5 x 10 -8 ) ( Table 2 ). This set of 23 highly significant SNPs were significantly associated with the higher level phenotype PAR4 ARS (p-value < 0.05, multiple linear regression) with multiple and adjusted R-squared values of 0.19 and 0.12, respectively.
To prioritize these variants for functional testing, we utilized publically available data to determine which of these SNPs coincided with markers of regulatory regions of the genome. The (H3K4me1), a marker of enhancer regions (2, 3, 13-15) ( Table 2) .
We prioritized SNP rs2912553, located in the first intron of the PCTP gene, for further analysis for the following reasons (Table 2 and Fig 1A) : (1 In concordance with our observation that platelets from black PRAX1 subjects contained higher amounts of PCTP, the high-expressing T allele was more common in blacks (allele frequency = 72%), while the low expressing C allele was more common in whites (allele frequency = 85%) (Fig 1C) , suggesting this variant may be causal for the differential expression of PCTP observed.
rs2912553 confers differential transcriptional potency
We cloned various sized fragments surrounding both alleles of rs2912553 into a luciferase vector containing a minimal promoter ( Fig. 2A) ) is another common SNP, rs2912552, which could potentially contribute to the transcriptional differences observed in 56 bp and larger fragments.
To test this, we generated 4 versions of the 130bp construct, which contains a large number of predicted GATA1, GATA2, and Ets factor binding sites not present in the 209bp fragment, containing all potential haplotypes of rs2912552 and rs2912553. We observed that rs2912552 genotype had no effect on transcription driven by this locus ( Figure 2C ). A predicted GATA1/2 binding site present in the 56bp construct, which is absent in the 43bp fragment, prompted us to further explore the role of GATA factors in regulating transcription from this genomic locus.
rs2912553 results in differential binding of a GATA1-containing protein complex
One hypothesis to explain the difference in transcriptional potency between the two alleles, is that the sequences containing the T allele had higher affinity for transcription factors (TF) and other regulatory molecules. To test this possibility, we performed electromobility shift assays (EMSAs) to investigate the interaction between DNA probes containing genomic sequence surrounding rs2912553 and nuclear extracts from K562 cells. 65 bp probes containing the T allele consistently recruited the highest molecular weight complex with higher affinity than probes containing the C allele (Fig 3A) . Quantification indicated the band containing this complex was 2-fold more intense in T alleles as compared to C , indicating increased TF binding (Fig 3B) .
Due to the transcription factor binding site predictions and CD34 ChIP-Seq data indicating their binding (Fig 1A) , we tested whether antibodies to GATA1 or GATA2 could disrupt or alter the mobility of the DNA:protein complex formed on the rs2912553 containing probes. To control for variation in the assay, we only analyzed the highest molecular weight band formed by addition of K562 nuclear extracts to the probes. As in Fig 3A, in the absence of a specific antibody, "T"-containing probes formed this highest molecular weight complex with greater affinity as indicated by the darker intensity (Fig. 3B, lanes 3 and 4) . We found that while anti-GATA1 antibodies disrupted formation of this complex, anti-GATA2 antibodies did not (Fig 3C) . Quantification of the shifted bands indicated that addition of the α-GATA1 antibody abrogated this difference significantly on the T allele (P = 0.004) and trending towards significance on the C allele (P = 0.07) (Fig 3D) . This indicates that the highest molecular weight complex, which is differentially recruited to the rs2912553 locus based on genotype, contains GATA1.
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GATA1 Regulates Transcription from the rs2912553 locus.
Given the evidence that GATA1 antibodies disrupted complex formation on rs2912553 containing probes, we investigated the effect of silencing or overexpression of GATA1 on luciferase expression from the 130bp construct, which contains predicted GATA1 binding sites.
Transfecting siRNAs directed against GATA1 resulted in a 70% reduction in GATA1 mRNA and protein level (Suppl. Figure 1 and Fig 4A) . This attenuation resulted in a 90% reduction in luciferase activity on constructs containing the T allele and a 60% reduction in constructs containing the C allele compared to a scrambled siRNA control (Fig 4B) . Conversely, overexpression of GATA1 resulted in a 20 and 80 fold increase in luciferase expression on the T and C alleles respectively (Fig 4C) . To confirm the role of GATA1 in regulating PCTP protein levels, we transfected a FLAG-GATA1 expression plasmid into 293 cells, which contain low levels of endogenous GATA1 and homozygous for the "C" allele at rs2912553 (Fig. 4D ). Over expression of GATA1 in these cells resulted in a 40% increase in PC-TP protein (Fig 4E) . This data supports the hypothesis that GATA1 contributes to regulation of the rs2912553 locus.
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Discussion
We have previously reported the results of a genome-wide eQTL analysis in which we identified genetic variants that are linked to the RNA level of a gene within 500kb (6) . One of the identified platelet eQTLs was SNP rs2912553 which is associated with PCTP gene expression.
Identification of this association is supported by allele-specific expression analysis of RNA-Seq data (6) . In this analysis we found a variant (rs2960062) We have previously reported that while the Alanine/Threonine variation in position 120 of the PAR4 receptor itself determines 48% of the variance in PAR4 reactivity, PC-TP protein levels accounted for 18%, making it a significant factor in determining PAR4 function (17) . PC-TP is best understood as having a role in regulating lipid and glucose metabolism in the liver, and the mechanism by which PC-TP regulates PAR4 function is still currently unknown (18) (19) (20) . We have made the following observations on the effect of the rs2912553 variant on PCTP expression: (1) The T-allele confers greater transcriptional potency than the C allele. (2) The T allele has a greater ability to recruit a GATA-1 containing protein complex than the C allele. (3) Reduction or enhancement of GATA1 levels results in a corresponding change in transcriptional activity.
A limitation of this study is a lack of the identification of the transcription factor that binds the first intron of PCTP and is altered by the rs2912553 genotype. Analysis of the DNA sequence predicts a number of ETS-factor binding sites which are altered by rs2912553 and attenuation of these factors with siRNA altered the enhancer potential of this locus. However, we have been unable to definitively confirm the importance of these factors to in vivo PCTP expression.
Better understanding of the significance behind loci identified in GWAS requires mechanistic insight as to how regulatory regions of the genome affect biology. We have utilized genotype, gene expression and physiological data to functionalize a racially dimorphic variant that regulates expression of PCTP, a regulator of platelet PAR4 function. More studies are needed to evaluate the role of this variant in contributing to racial differences in platelet function in both healthy and pathological states.
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